RR-A1 is a long-acting receptor agonist designed to overcome the short half-life of natural incretin hormones, which are typically degraded within 1-2 minutes. RR-A1 uses an albumin-binding strategy for systemic protraction. The peptide features optimized fatty acid and linker combinations that maximize albumin binding while maintaining receptor potency. RR-A1 acts on incretin receptors, which belong to the secretin family of G protein-coupled receptors (GPCRs), stimulating the adenylate cyclase pathway to produce downstream effects. - Glucose-dependent insulin secretion: Enhanced during hyperglycemia - Glucagon suppression: Reduces hepatic glucose output - Delayed gastric emptying: Prolongs digestion and promotes satiety - Central appetite regulation: Decreases appetite via leptin-mediated hypothalamic pathways Clinical research programs have studied cardiovascular outcomes, demonstrating potential cardioprotective properties through anti-inflammatory pathway modulation.
RR-A1: GLP-1 Receptor Agonist Research Guide
Understanding RR-A1, the long-acting receptor agonist studied for metabolic regulation and glucose metabolism.